Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy? (Q37921903)

25 August 2017

1 reference

title

Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy? (English)

1 reference

25 August 2017

0 references

2

Michaela Diamant

1 reference

25 August 2017

Daniel H van Raalte

1

1 reference

25 August 2017

1 August 2011

1 reference

Diabetes Research and Clinical Practice

25 August 2017

1 reference

25 August 2017

93 Suppl 1

1 reference

25 August 2017

S37-46

1 reference

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Preservation of beta-cell function by targeting beta-cell mass

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Islets in type 2 diabetes: in honor of Dr. Robert C. Turner

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Relationship between beta-cell mass and fasting blood glucose concentration in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Glucolipotoxicity: fuel excess and beta-cell dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

The role for endoplasmic reticulum stress in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

The sensitivity of pancreatic beta-cells to mitochondrial injuries triggered by lipotoxicity and oxidative stress.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Transient oxidative stress damages mitochondrial machinery inducing persistent beta-cell dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

beta-cell failure in diabetes and preservation by clinical treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Islet beta cell failure in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Minireview: Secondary beta-cell failure in type 2 diabetes--a convergence of glucotoxicity and lipotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Free fatty acid-induced reduction in glucose-stimulated insulin secretion: evidence for a role of oxidative stress in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Glucolipotoxicity of the pancreatic beta-cell: myth or reality?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

An update on lipotoxic endoplasmic reticulum stress in pancreatic beta-cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Fatty acids and glucolipotoxicity in the pathogenesis of Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Elevation of plasma fatty acids by ten-hour intralipid infusion has no effect on basal or glucose-stimulated insulin secretion in normal man

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Acute elevation of NEFA causes hyperinsulinemia without effect on insulin secretion rate in healthy human subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Prolonged increase of plasma non-esterified fatty acids fully abolishes the stimulatory effect of 24 hours of moderate hyperglycaemia on insulin sensitivity and pancreatic beta-cell function in obese men.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Short-term intensive insulin therapy in newly diagnosed type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Lipotoxicity in human pancreatic islets and the protective effect of metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Sulfonylurea induced beta-cell apoptosis in cultured human islets

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Differential effect of sulfonylureas on production of reactive oxygen species and apoptosis in cultured pancreatic beta-cell line, MIN6.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Beta-cell preservation with thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Rosiglitazone counteracts palmitate-induced beta-cell dysfunction by suppression of MAP kinase, inducible nitric oxide synthase and caspase 3 activities

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic beta-cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Increased insulin demand promotes while pioglitazone prevents pancreatic beta cell apoptosis in Wfs1 knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Glucagon-like peptide-1 prevents beta cell glucolipotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2811%2970012-2

7 January 2021

10.1016/S0168-8227(11)70012-2

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21864750